Cover Image

Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma

In the TOURMALINE-MM3 study, post-autologous stem cell transplantation maintenance therapy with the oral proteasome inhibitor ixazomib versus placebo significantly improved progression-free survival (PFS), with a favorable safety profile. With ixazomib versus placebo maintenance, deepening responses...

Full description

Saved in:
Bibliographic Details
Main Authors: Goldschmidt, Hartmut (Author) , Dimopoulos, Meletios A. (Author) , Rajkumar, S. Vincent (Author) , Weisel, Katja (Author) , Moreau, Philippe (Author) , Chng, Wee Joo (Author) , Mikala, Gábor (Author) , Cavo, Michele (Author) , Ramasamy, Karthik (Author) , Suryanarayan, Kaveri (Author) , Teng, Zhaoyang (Author) , Labotka, Richard (Author) , Mateos, Maria-Victoria (Author)
Format: Article (Journal)
Language:English
Published: 23 April 2020
In: Leukemia
Year: 2020, Volume: 34, Issue: 11, Pages: 3019-3027
ISSN:1476-5551
DOI:10.1038/s41375-020-0819-8
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41375-020-0819-8
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41375-020-0819-8
Get full text
Author Notes:Hartmut Goldschmidt, Meletios A. Dimopoulos, S. Vincent Rajkumar, Katja C. Weisel, Philippe Moreau, Wee-Joo Chng, Gábor Mikala, Michele Cavo, Karthik Ramasamy, Kaveri Suryanarayan, Zhaoyang Teng, Richard Labotka, Maria Victoria Mateos
Description
Summary:In the TOURMALINE-MM3 study, post-autologous stem cell transplantation maintenance therapy with the oral proteasome inhibitor ixazomib versus placebo significantly improved progression-free survival (PFS), with a favorable safety profile. With ixazomib versus placebo maintenance, deepening responses occurred in 139/302 (46%) versus 60/187 (32%) patients with very good partial response or partial response (VGPR/PR) at study entry (relative risk 1.41, P = 0.004), and median time to best confirmed deepened response was 19.9 versus 30.8 months (24-month rate: 54.2 versus 41.4%; hazard ratio (HR): 1.384; P = 0.0342). Median PFS in patients with VGPR/PR at study entry was 26.2 versus 18.5 months (HR: 0.636, P < 0.001) with ixazomib versus placebo; in a pooled analysis across arms, in patients with versus without deepening responses, the median PFS was not reached versus 15.9 months (HR: 0.245, P < 0.001). In patients with deepening responses, 24-month PFS rate was 77.4 versus 68.3% with ixazomib versus placebo (HR: 0.831; P = 0.466); in patients without deepening responses, median PFS was 17.9 versus 14.1 months (HR: 0.741; P = 0.028). These analyses demonstrate the significantly higher rate of deepening responses with ixazomib versus placebo maintenance and the association between deepening response and prolonged PFS.
Item Description:Gesehen am 01.12.2021
Physical Description:Online Resource
ISSN:1476-5551
DOI:10.1038/s41375-020-0819-8

Similar Items